Navigation Links
Bioenergy D-Ribose Achieves Highest Safety Standard
Date:11/20/2008

MINNEAPOLIS, Nov. 20 /PRNewswire/ -- Integrative life science company Bioenergy, Inc. has achieved GRAS status (generally recognized as safe) from the U.S. Food and Drug Administration (FDA) for its core energy nutrient D-ribose, a naturally occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP) -- an essential energy compound.

"The FDA's written response that it has reviewed the submitted safety evidence and has no questions about the GRAS determination for D-ribose is the government's highest recognition of a food ingredient for safety and purity," said Raj Khankari, Ph.D., CEO of Bioenergy, Inc. The company has held "self-affirmed" GRAS status for years. "Today, we are gratified that the FDA has officially validated our assessment."

"The FDA's 'no questions letter' signals to the major food and beverage manufacturers that we have invested all the resources possible to guarantee the quality and safety of our D-ribose products for the benefit of customers and consumers."

Bioenergy has amassed a large body of scientific literature regarding uses of ribose for people across all age and health categories. The company has more than 40,000 customers for its proprietary Corvalen products alone, and millions worldwide use Bioenergy ribose in other products. It is commonly found in functional foods like energy bars (Detour, FastFuel, Marathon) and beverages (SoBe Adrenaline Rush, Vitamin Water, Snapple Antioxidant Water). Currently, Bioenergy D-ribose is included as an ingredient in approximately 100 products.

In larger quantities as a Medical Food, D-Ribose also has been shown to assist patients with compromised heart function and is also widely used by patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS).

Bioenergy, Inc. (http://www.bioenergy.com) is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose for health and wellness. In addition to a pharmaceutical subsidiary, Bioenergy has two other companies. Bioenergy Life Science, Inc. manufactures and sells D-ribose as an ingredient to nutraceutical firms for beverages and foods; as a medical food through doctors and clinics; and as a dietary supplement for energy recovery (reduces fatigue, muscle pain, soreness and stiffness following exercise). Viacell, LLC is developing technology related to the enhancement of blood components.


'/>"/>
SOURCE Bioenergy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Media Advisory - Atlantica BioEnergy Task Force Leaders Roundtable
2. Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production
3. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
4. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
5. Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock
6. Raj Khankari Named Bioenergy, Inc., CEO
7. Atlantica BioEnergy Task Force Unveiled
8. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
9. BioEnergy International Facility Opens in Bay State
10. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
11. D-Ribose Helps Energy-Starved Hearts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, ... the "Company"), announced that on January 14, 2017 the ... under which the Company will terminate certain employees associated ... Diagnostics, Inc.  The Company commenced terminations on January 16, ... 30 days.  The Company may pay severance benefits in ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... how current market conditions have influenced the most recent ... Regulus Therapeutics Inc. (NASDAQ: RGLS ), Abeona ... Inc. (NASDAQ: TBPH ), and Sage Therapeutics ... new research report by Grand View Research, global Biotech market size ...
(Date:1/20/2017)... January 20, 2017 http://www.Financialbuzz.com ... one of leading causes of death worldwide. There were ... number of cancer related deaths increased gradually over time, ... incidence rate of various cancers continues to drive demand ... report by Global Market Insights, Inc. cancer biological therapy ...
Breaking Biology Technology:
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
Breaking Biology News(10 mins):